• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低风险肾移植人群中抗胸腺细胞球蛋白诱导给药策略:三日还是四日?

Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days?

作者信息

Hardinger Karen L, Rasu Rafia S, Skelton Rebecca, Miller Brent W, Brennan Daniel C

机构信息

Division of Pharmacy Practice and Administration, University of Missouri-Kansas City, Kansas City, MO 64108, USA.

出版信息

J Transplant. 2010;2010:957549. doi: 10.1155/2010/957549. Epub 2010 Nov 7.

DOI:10.1155/2010/957549
PMID:21076531
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2975077/
Abstract

The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n = 59) versus 2 mg/kg for 3 days (n = 59), in a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group (P = .983). Renal function and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be thrombocytopenic on day 2 (4% versus 28%, P = .04). Length of stay tended to be longer for the 1.5 mg/kg group (6.0 ± 3.7 versus 5.1 ± 1.9 days P = .104). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group (P = .122). Conclusions. Shorter, more intense dosing of rATG is safe and effective. The 3-day dose strategy resulted in a clinically shorter length of stay and may result in cost savings.

摘要

兔抗胸腺细胞球蛋白(rATG)诱导治疗的最佳剂量和疗程尚未确定。方法。在一项回顾性队列研究中,我们比较了两种给药方案的安全性和有效性,即rATG 1.5mg/kg,共4天(n = 59)与2mg/kg,共3天(n = 59)。结果。两组的两年无排斥生存率均为95%(P = 0.983)。肾功能和感染率相似。白细胞减少症的发生率相似,尽管2mg/kg组在第2天更易出现血小板减少(4%对28%,P = .04))。1.5mg/kg组的住院时间往往更长(6.0±3.7天对5.1±1.9天,P = 0.104)。2mg/kg组每位患者的rATG成本节省了920美元(P = 0.122)。结论。更短、强度更大剂量的rATG是安全有效的。3天剂量方案导致临床住院时间缩短,可能节省成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/8ea505fd151a/JTRAN2010-957549.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/459010c7e7a8/JTRAN2010-957549.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/9cf3d030e949/JTRAN2010-957549.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/8ea505fd151a/JTRAN2010-957549.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/459010c7e7a8/JTRAN2010-957549.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/9cf3d030e949/JTRAN2010-957549.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fb/2975077/8ea505fd151a/JTRAN2010-957549.003.jpg

相似文献

1
Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days?低风险肾移植人群中抗胸腺细胞球蛋白诱导给药策略:三日还是四日?
J Transplant. 2010;2010:957549. doi: 10.1155/2010/957549. Epub 2010 Nov 7.
2
Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.兔抗胸腺细胞球蛋白(即胸腺球蛋白):其在预防和治疗急性肾移植排斥反应中的应用综述
Drugs. 2009 Jul 30;69(11):1483-512. doi: 10.2165/00003495-200969110-00007.
3
Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.在新诊断的肾移植受者中,延长住院至门诊期兔抗胸腺细胞球蛋白诱导的疗效和安全性:6 个月的结果。
Transplantation. 2012 Sep 15;94(5):506-12. doi: 10.1097/TP.0b013e31825c58c0.
4
Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras.早期撤激素方案下的肾移植:两个时代中兔抗胸腺细胞球蛋白诱导剂量的比较。
Am J Nephrol. 2013;38(5):397-404. doi: 10.1159/000355620. Epub 2013 Oct 26.
5
Low-Dose Antithymocyte Globulin Has No Disadvantages to Standard Higher Dose in Pediatric Kidney Transplant Recipients: Report From the Pediatric Nephrology Research Consortium.低剂量抗胸腺细胞球蛋白对小儿肾移植受者并无劣于标准高剂量:来自小儿肾脏病研究联盟的报告。
Kidney Int Rep. 2021 Jan 17;6(4):995-1002. doi: 10.1016/j.ekir.2021.01.007. eCollection 2021 Apr.
6
Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal.在早期撤用皮质类固醇的肾移植中,兔抗胸腺细胞诱导治疗的递送剂量微小变化的影响。
Transplantation. 2012 Aug 27;94(4):325-30. doi: 10.1097/TP.0b013e318257ad1a.
7
Comparative Efficacy and Safety of Low-Dose Versus Standard-Dose Rabbit Antithymocyte Globulin Induction Strategy in Kidney Transplant Recipients: Insights From a Single-Center Experience in North India.低剂量与标准剂量兔抗胸腺细胞球蛋白诱导策略在肾移植受者中的疗效与安全性比较:来自印度北部单中心经验的见解
Cureus. 2024 Sep 20;16(9):e69770. doi: 10.7759/cureus.69770. eCollection 2024 Sep.
8
Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.基于体重的兔抗胸腺细胞球蛋白诱导给药方案用于肾移植受者的评估。
Pharmacotherapy. 2015 Aug;35(8):748-54. doi: 10.1002/phar.1624. Epub 2015 Aug 3.
9
Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.降低剂量兔抗胸腺细胞球蛋白诱导预防高危肾移植受者急性排斥反应。
Transplantation. 2009 Oct 15;88(7):891-6. doi: 10.1097/TP.0b013e3181b6f38c.
10
Ideal Body Weight-Based Dosing of Rabbit Antithymocyte Globulin for Cost Minimization in Kidney Transplantation.基于理想体重的兔抗胸腺细胞球蛋白剂量用于降低肾移植成本。
Prog Transplant. 2021 Jun;31(2):184-189. doi: 10.1177/15269248211003257. Epub 2021 Mar 18.

引用本文的文献

1
Toll-like receptors and damage-associated molecular patterns in the pathogenesis of heart transplant rejection. toll 样受体及损伤相关分子模式在心脏移植排斥反应发病机制中的作用。
Mol Cell Biochem. 2022 Dec;477(12):2841-2850. doi: 10.1007/s11010-022-04491-4. Epub 2022 Jun 9.
2
Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection.免疫治疗诱导对不同免疫排斥风险的肾移植患者结局和移植物存活的影响。
BMC Nephrol. 2019 Aug 13;20(1):314. doi: 10.1186/s12882-019-1497-5.
3
Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation.

本文引用的文献

1
Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients.高危肾移植受者诱导治疗中胸腺球蛋白剂量的优化
Transplantation. 2008 May 27;85(10):1425-30. doi: 10.1097/TP.0b013e31816dd596.
2
Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.肾移植中兔抗胸腺细胞球蛋白单剂量与分剂量诱导的随机试验:中期报告
Transplantation. 2008 May 27;85(10):1391-9. doi: 10.1097/TP.0b013e3181722fad.
3
Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation.
肾移植中量身定制的兔抗胸腺细胞球蛋白诱导剂量
Transplant Direct. 2018 Feb 2;4(2):e343. doi: 10.1097/TXD.0000000000000765. eCollection 2018 Feb.
4
Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.肾移植患者中阿仑单抗与抗胸腺细胞球蛋白诱导疗法的比较:随机对照试验的系统评价和荟萃分析
Medicine (Baltimore). 2017 Jul;96(28):e7151. doi: 10.1097/MD.0000000000007151.
5
Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center.阿仑单抗与标准免疫诱导对设拉子移植中心早期肾移植功能影响的比较
Int J Organ Transplant Med. 2015;6(4):150-6. Epub 2015 Nov 1.
6
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage.抗胸腺细胞球蛋白在肾移植中的诱导作用:文献综述与当前应用
J Nephropathol. 2015 Oct;4(4):110-5. doi: 10.12860/jnp.2015.21. Epub 2015 Oct 1.
7
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.兔抗胸腺细胞球蛋白(即复宁®)在实体器官移植、干细胞移植和自身免疫性疾病中的新应用方向
Drugs. 2014 Sep;74(14):1605-34. doi: 10.1007/s40265-014-0277-6.
8
Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study.低剂量抗胸腺细胞球蛋白在早期停用类固醇的非致敏肾移植受者中的免疫表型分析及疗效:一项随机试验研究
PLoS One. 2014 Aug 11;9(8):e104408. doi: 10.1371/journal.pone.0104408. eCollection 2014.
9
Adding thymoglobuline to the conventional immunosuppressant regimen in kidney transplantation: A cost-benefit analysis.肾移植中在传统免疫抑制方案中添加抗胸腺细胞球蛋白:一项成本效益分析。
Caspian J Intern Med. 2012 Fall;3(4):514-8.
两种剂量的胸腺球蛋白用于肾移植短期诱导的比较。
Transpl Int. 2006 Aug;19(8):629-35. doi: 10.1111/j.1432-2277.2006.00270.x.
4
Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage.门静脉-肠引流胰腺移植中隔日使用抗胸腺细胞球蛋白诱导治疗的经验
Transplant Proc. 2005 Oct;37(8):3546-8. doi: 10.1016/j.transproceed.2005.09.084.
5
A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.一项针对成年尸体肾移植受者术中与术后使用抗胸腺细胞球蛋白的前瞻性、随机临床试验。
Transplantation. 2003 Sep 15;76(5):798-802. doi: 10.1097/01.TP.0000081042.67285.91.
6
Tolerogenic immunosuppression for organ transplantation.器官移植的耐受性免疫抑制
Lancet. 2003 May 3;361(9368):1502-10. doi: 10.1016/s0140-6736(03)13175-3.
7
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients.基于CD3 +淋巴细胞计数的间歇性给药的胸腺球蛋白诱导疗法在肾移植和肾胰联合移植受者中的安全性、有效性及成本分析。
Transplantation. 2002 May 15;73(9):1514-8. doi: 10.1097/00007890-200205150-00025.
8
Short course induction immunosuppression with thymoglobulin for renal transplant recipients.肾移植受者使用抗胸腺细胞球蛋白进行短疗程诱导免疫抑制治疗。
Transplantation. 2002 Feb 15;73(3):473-5. doi: 10.1097/00007890-200202150-00025.
9
Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model.非人类灵长类动物模型中抗胸腺细胞球蛋白免疫抑制活性的相关机制。
Transplantation. 2001 Feb 15;71(3):460-8. doi: 10.1097/00007890-200102150-00021.
10
A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.成人肾移植受者诱导免疫抑制治疗中,抗胸腺细胞球蛋白与抗淋巴细胞球蛋白的随机双盲对照研究。
Transplantation. 1999 Apr 15;67(7):1011-8. doi: 10.1097/00007890-199904150-00013.